Editas Medicine (EDIT) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Editas Medicine Announces Second Quarter 2017 Results and Update
August 9, 2017 4:03 PM EDTLeber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials
Achieved research milestone in Juno Therapeutics, Inc., collaboration
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the second quarter ended June 30, 2017, and provided an update on recent achievements and upcoming events.
This quarter, we made critical progress in advancing our LCA10 product candidate toward the clinic, as well as in our broader pipeline, said Katrine Bosley, President and Chief Executive... More
